Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy

Next Previous
Trial Profile

An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluciclovine 18F (Primary)
  • Indications Brain metastases
  • Focus Diagnostic use
  • Acronyms PURSUE
  • Sponsors Blue Earth Diagnostics

Most Recent Events

  • 06 Jun 2023 Results assessing diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy presented at the 59th Annual Meeting of the American Society of Clinical Oncology
  • 20 Dec 2022 Status changed from active, no longer recruiting to completed.
  • 08 Jun 2022 According to a Blue Earth Diagnostics media release, results from this study will be presented at the upcoming scientific meetings later this year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top